Improving Disease Management through Innovative Microbiology Solutions

DeepChek®
Genotyping through NGS & Sanger Sequencing
  • HIV
  • SARS CoV-2
  • HCV
  • TB
  • 16S RNA
More information

ABL Diagnostics and CDL Pharma Secure a Multi-year International Contract of up to €2.7 Million Through 2031

https://www.businesswire.com/news/home/20260611674142/en/ABL-Diagnostics-and-CDL-Pharma-Secure-a-Multi-year-International-Contract-of-up-to-%E2%82%AC2.7-Million-Through-2031

Read More

ABL Diagnostics Showcases Scientific Progress at EMHH 2026, Supporting Strategic Positioning in Molecular Technologies

https://www.einpresswire.com/article/918127065/abl-diagnostics-showcases-scientific-progress-at-emhh-2026-supporting-strategic-positioning-in-molecular-technologies

Read More

ABL Diagnostics Advances Platform-Agnostic NGS Strategy Through DeepChek® Verification on Element Biosciences’ AVITI™

https://www.einpresswire.com/article/918135269/abl-diagnostics-advances-platform-agnostic-ngs-strategy-through-deepchek-verification-on-element-biosciences-aviti

Read More

ABL Diagnostics Deepens Laboratory Footprint with Launch of HybridChek for HIV and Tuberculosis Whole Genome Sequencing

https://www.einpresswire.com/article/917550254/abl-diagnostics-deepens-laboratory-footprint-with-launch-of-hybridchek-for-hiv-and-tuberculosis-whole-genome-sequencing

Read More

Subscribe to our newsletter

Scroll to Top